×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
02:36 pm
nvo
Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]
Low
Report
Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]
2/4
02:31 pm
nvo
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]
Low
Report
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]
2/4
02:14 pm
nvo
Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]
Low
Report
Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]
2/4
02:14 pm
nvo
Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]
Low
Report
Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]
2/4
01:58 pm
nvo
Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]
Low
Report
Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]
2/4
12:45 pm
nvo
Novo Nordisk Q4: Slumping Due To Weak Guidance [Seeking Alpha]
Low
Report
Novo Nordisk Q4: Slumping Due To Weak Guidance [Seeking Alpha]
2/4
12:44 pm
nvo
Novo to launch Ozempic pill for diabetes in second quarter of 2026 [BNN Bloomberg (Canada)]
Low
Report
Novo to launch Ozempic pill for diabetes in second quarter of 2026 [BNN Bloomberg (Canada)]
2/4
12:27 pm
nvo
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade) [Seeking Alpha]
Low
Report
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade) [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
09:28 am
nvo
Form IRANNOTICE NOVO NORDISK A S
Low
Report
Form IRANNOTICE NOVO NORDISK A S
2/4
09:26 am
nvo
Form 20-F NOVO NORDISK A S For: Dec 31
Low
Report
Form 20-F NOVO NORDISK A S For: Dec 31
2/4
08:44 am
nvo
Form 6-K NOVO NORDISK A S For: Dec 31
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 31
2/3
12:48 pm
nvo
Form 6-K NOVO NORDISK A S For: Dec 31
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 31
2/3
12:29 pm
nvo
Form 6-K NOVO NORDISK A S For: Feb 03
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 03
2/2
12:44 pm
nvo
Form 6-K NOVO NORDISK A S For: Feb 02
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 02
2/2
06:09 am
nvo
Form 6-K NOVO NORDISK A S For: Jan 31
Low
Report
Form 6-K NOVO NORDISK A S For: Jan 31
12/23
09:57 am
nvo
Form 6-K NOVO NORDISK A S For: Dec 22
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 22
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: